SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Clin Cancer Res
; 23(19): 5836-5845, 2017 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-28679774
Full text:
1
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Uterine Neoplasms
/
Carcinosarcoma
/
Receptor, ErbB-2
/
Immunoconjugates
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2017
Type:
Article